Last updated: November 12, 2024
Sponsor: First Affiliated Hospital of Fujian Medical University
Overall Status: Active - Recruiting
Phase
1
Condition
Neoplasms
Treatment
68Ga-JH12
Clinical Study ID
NCT06688188
FirstAHFujian-68Ga-JH12
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Various solid tumors with available histopathological findings
Signed informed consent
Exclusion
Exclusion Criteria:
pregnant or lactational women
who suffered from severe hepatic and renal insufficiency
Study Design
Total Participants: 5
Treatment Group(s): 1
Primary Treatment: 68Ga-JH12
Phase: 1
Study Start date:
November 01, 2024
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian 350005
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.